We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

In Win For Barr, Court Denies Tamoxifen Rehearing

Law360 (September 18, 2006, 12:00 AM EDT) -- Marking a victory for Barr Pharmaceuticals Inc. in a long-running case over authorized generics, the U.S. Court of Appeals for the Second Circuit has denied a bid for rehearing by a group of consumers in the Tamoxifen Citrate antitrust lawsuits.

Barr, the defendant in the class actions, along with AstraZeneca Pharmaceuticals, said on Monday that the plaintiffs' petitions for rehearing and rehearing en banc were denied on Sept. 15, ending the litigation before the Second Circuit.

"The court's denial of the rehearing petitions re-enforces the growing...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.